Healthcare / Drug Manufacturers - Specialty & GenericNSE
$181.03
+0.37 (+0.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-293.3M · quality 46.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.3B
P/E
20.3x
↓EV/EBITDA
14.3x
↑ROE
10.8%
↑Gross Margin
46.4%
↓Debt/Equity
0.32
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+19.2%
FCF CAGR
—
FCF margin
-32.1%
FCF / Net income
-2.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.35B · net income $301.7M · FCF $-755.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.35B | $2.35B | $1.98B | $1.54B | $1.39B |
| Net Income | $301.7M | $301.7M | $267.0M | $146.0M | $104.5M |
| EBITDA | $478.4M | $478.4M | $426.3M | $286.3M | $204.8M |
| EPS | 8.91 | 8.91 | 16.60 | 4.49 | 3.28 |
| Gross Margin | 46.4% | 46.4% | 47.3% | 47.6% | 44.5% |
| Operating Margin | 14.0% | 14.0% | 14.3% | 13.7% | 10.3% |
| Net Margin | 12.8% | 12.8% | 13.5% | 9.5% | 7.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.32 | 0.32 | 0.24 | 0.18 | 0.15 |
| Current Ratio | 1.83 | 1.83 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-755.5M | $-755.5M | $-293.3M | $-79.9M | $-12.3M |
| Returns | |||||
| ROE | 10.8% | 10.8% | 13.2% | 8.3% | 6.9% |
| Valuation | |||||
| P/E | 20.29 | 20.29 | 9.93 | 41.23 | 23.36 |
| EV/EBITDA | 14.34 | 14.34 | 13.64 | 21.48 | 12.04 |
| P/B | 2.19 | 2.19 | 2.68 | 3.42 | 1.61 |
| Growth & Yield | |||||
| Revenue Growth | 18.7% | 18.7% | 29.1% | 10.6% | — |
| EPS Growth | -46.3% | -46.3% | 270.0% | 36.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
21.7%
EPS terminal req.
$16.06
Spread vs growth
-68.0%
5Y implied EPS CAGR
16.9%
EPS terminal req.
$19.44
Spread vs growth
-63.2%
10Y implied EPS CAGR
13.4%
EPS terminal req.
$31.30
Spread vs growth
-59.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-19.4%
Start / end P/E
13.6x → 20.5x
EPS bridge
16.60 → 8.91
Residual
-23.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.